Get the Stockscreener App
4.14
3.50%
0.14
After Hours:
4.14
Insight Molecular Diagnostics Inc stock is traded at $4.14, with a volume of 159.29K.
It is up +3.50% in the last 24 hours and down -28.00% over the past month.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.
See More
Previous Close:
$4.00
Open:
$4.12
24h Volume:
159.29K
Relative Volume:
2.18
Market Cap:
$118.75M
Revenue:
$4.40M
Net Income/Loss:
$-60.78M
P/E Ratio:
-1.4626
EPS:
-2.8305
Net Cash Flow:
$-23.91M
1W Performance:
-5.48%
1M Performance:
-28.00%
6M Performance:
+26.99%
1Y Performance:
+0.00%
1-Day Range:
$3.69
$4.45
1-Week Range:
$3.44
$4.47
52-Week Range:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Name
Insight Molecular Diagnostics Inc
Sector
Industry
Phone
949-409-7600
Address
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
4.14 | 114.74M | 4.40M | -60.78M | -23.91M | -2.8305 |
TMO
Thermo Fisher Scientific Inc
|
490.77 | 182.14B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
187.15 | 134.43B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.72 | 45.40B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.98 | 32.27B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.32 | 29.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Initiated | Lake Street | Buy |
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
Insight Molecular Diagnostics Inc Stock (IMDX) Latest News
Insight Molecular Diagnostics Inc. Q4 2025 earnings preview - MSN
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Molecular Diagnostics Market Is Going to BoomKey Factors Driving Unstoppable Growth - openPR.com
IMDX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference - The Manila Times
iMDx CEO, CFO to join Needham conference after March 26 results - Stock Titan
Oncocyte : to Begin Trading on the Nasdaq Stock Market on March 8, 2021 - marketscreener.com
HTGMQ (HTG Molecular Diagnostics) PNK at $0.0001 19 Mar 2026: top gainer insight - Meyka
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Assertio Therapeutics (ASRT) and LENSAR (LNSR) - The Globe and Mail
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Capital And GraftAssureDx Milestones - Yahoo Finance
Certain Restricted Stock Units of Insight Molecular Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2026. - marketscreener.com
Certain Warrants of Insight Molecular Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2026. - marketscreener.com
Insight Molecular Diagnostics (IMDX) Advances with GraftAssure T - GuruFocus
Insight Molecular Diagnostics Inc Highlights New Peer-Reviewed Study Demonstrating GraftAssure Assay Technology Superiority - marketscreener.com
Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score - The Manila Times
Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model Score - Bitget
Insight Molecular Diagnostics Nears FDA Submission for Kidney Transplant Rejection Test Kit - Clinical Lab Products
Insight Molecular Diagnostics Nears FDA Submission with GraftAssureDx Milestones - Zenopa
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission - Bitget
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Insight Molecular Diagnostics completes key milestones advancing Graftassuredx toward FDA submission - marketscreener.com
Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission - TradingView
Kidney transplant test GraftAssureDx nears FDA submission in $2B market - Stock Titan
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And GraftAssureDx Catalyst - Yahoo Finance
Insight Molecular Diagnostics enters agreement with Quest DiagnosticsSEC filing - marketscreener.com
Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement - TipRanks
In Insight Molecular Diagnostics Inc. Enters into A Specimen Collection Agreement with Quest Diagnostics Incorporated - marketscreener.com
Insight Molecular (IMDX) taps Quest Diagnostics for GraftAssureCore test collection - Stock Titan
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Insight Molecular Diagnostics Inc. has reached a service agreement with Quest Diagnostics. - Bitget
Insight Molecular Diagnostics (IMDX) Price Target Increased by 19.05% to 8.50 - Nasdaq
Kidney Transplant Rejection Market Overview: Major Segments, Strategic Developments, and Leading Companies - openPR.com
IMDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Molecular Biology Analyzers Market Set to Boom by 2033: - openPR.com
Insight Molecular (IMDX) Sees Analyst Price Target Raised to $12 - GuruFocus
Of Note: Nashville Zoo adds to board - Nashville Post
Insider Stock Purchases: February 13, 2026 - Quiver Quantitative
Insight Molecular Diagnostics Raises Capital to Advance Transplant R&D - TipRanks
Insight Molecular Diagnostics Signs Multiple Material Agreements - TradingView
From $54B to $85B: A Promising Decade for North America IVD - GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Imdx announces $26.0 million registered direct offering - marketscreener.com
Insight Molecular Diagnostics (IMDX) Secures $26M in Direct Stoc - GuruFocus
Insight Molecular Diagnostics prices $26M registered direct offering; shares down - MSN
Insight Molecular Diagnostics Provides Updated Investor Presentation Materials - TipRanks
iMDx Announces $26.0 Million Registered Direct Offering - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Boston Scientific (BSX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Steris (STE) and Roche Holding AG (OtherRHHVF) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Artivion (AORT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Stryker (SYK), NewAmsterdam Pharma Company (NAMS) and Resmed (RMD) - The Globe and Mail
Gastric Cancer Diagnostic Procedure Market to Grow at a CAGR of 6.53% - industrytoday.co.uk
Urinary Tract Infection Testing Market | Global Market Analysis Report2036 - Future Market Insights
Insight Molecular Diagnostics Inc Stock (IMDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):